Goldman Sachs leads $62m funding in China's Fountain Medical

Goldman Sachs has led a $62 million Series D round of financing in Fountain Medical Development Limited, a Chinese clinical-stage contract research organization (CRO) offering one-stop services to pharmaceutical and medical device companies.

China-based biomedical venture capital firm Lilly Asia Ventures also participated in the investment, according to a statement on Friday.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter